Bismuth absorption and myoclonic encephalopathy during bismuth subsalicylate therapy.
Mendelowitz
P C
PC
Presbyterian Hospital, New York, New York.
Hoffman
R S
RS
Weber
S
S
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000930:Antidiarrheals / Q000493:pharmacokinetics / Q000506:poisoning*; D001729:Bismuth / Q000493:pharmacokinetics / Q000506:poisoning*; D001927:Brain Diseases / Q000139:chemically induced*; D003967:Diarrhea / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007408:Intestinal Absorption; D008297:Male; D008875:Middle Aged; D009207:Myoclonus / Q000139:chemically induced*; D009942:Organometallic Compounds / Q000493:pharmacokinetics / Q000506:poisoning*; D012459:Salicylates / Q000493:pharmacokinetics / Q000506:poisoning*
D000930:Antidiarrheals; D009942:Organometallic Compounds; D012459:Salicylates; C015715:bismuth subsalicylate; D001729:Bismuth